Literature DB >> 30855393

Lymphedema Incidence After Axillary Lymph Node Dissection: Quantifying the Impact of Radiation and the Lymphatic Microsurgical Preventive Healing Approach.

Anna Rose Johnson, Sarah Kimball1, Sherise Epstein, Abram Recht2, Samuel J Lin, Bernard T Lee, Ted A James3, Dhruv Singhal.   

Abstract

BACKGROUND: Axillary surgery and radiotherapy are important aspects of breast cancer treatment associated with development of lymphedema. Studies demonstrate that Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) may greatly reduce the incidence of lymphedema in high-risk groups. The objective of this study is to summarize the evidence relating lymphedema incidence to axillary lymph node dissection (ALND), regional lymph node radiation (RLNR) therapy, and LYMPHA.
METHODS: We performed a literature search to identify studies involving breast cancer patients undergoing ALND with or without RLNR. Our primary outcome was the development of lymphedema. We analyzed the effect of LYMPHA on lymphedema incidence. We chose the DerSimonian and Laird random-effects meta-analytic model owing to the clinical, methodological, and statistical heterogeneity of studies.
RESULTS: Our search strategy yielded 1476 articles. After screening, 19 studies were included. Data were extracted from 3035 patients, 711 of whom had lymphedema. The lymphedema rate was significantly higher when RLNR was administered with ALND compared with ALND alone (P < 0.001). The pooled cumulative incidence of lymphedema was 14.1% in patients undergoing ALND versus 2.1% in those undergoing LYMPHA and ALND (P = 0.029). The pooled cumulative incidence of lymphedema was 33.4% in those undergoing ALND and RLNR versus 10.3% in those undergoing ALND, RLNR, and LYMPHA (P = 0.004).
CONCLUSION: Axillary lymph node dissection and RLNR are important interventions to obtain regional control for many patients but were found to constitute an increased risk of development of lymphedema. Our findings support that LYMPHA, a preventive surgical technique, may reduce the risk of breast cancer-related lymphedema in high-risk patients.

Entities:  

Mesh:

Year:  2019        PMID: 30855393     DOI: 10.1097/SAP.0000000000001864

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  12 in total

Review 1.  Outcomes of Lymphovenous Anastomosis for Upper Extremity Lymphedema: A Systematic Review.

Authors:  Nikita Gupta; Erik M Verhey; Ricardo A Torres-Guzman; Francisco R Avila; Antonio Jorge Forte; Alanna M Rebecca; Chad M Teven
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-08-25

Review 2.  Lymphedema: Conventional to Cutting Edge Treatment.

Authors:  Duane Wang; Daniel Lyons; Roman Skoracki
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

3.  A Murine Tail Lymphedema Model.

Authors:  Aladdin H Hassanein; Mithun Sinha; Colby R Neumann; Ganesh Mohan; Imran Khan; Chandan K Sen
Journal:  J Vis Exp       Date:  2021-02-10       Impact factor: 1.355

4.  Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) for Lymphedema Prevention after Axillary Lymph Node Dissection-A Single Institution Experience and Feasibility of Technique.

Authors:  Kelsey Lipman; Anna Luan; Kimberly Stone; Irene Wapnir; Mardi Karin; Dung Nguyen
Journal:  J Clin Med       Date:  2021-12-24       Impact factor: 4.241

5.  Simultaneous Lymphatic Superficial Circumflex Iliac Artery Perforator Flap Transfer from the Zone 4 Region in Autologous Breast Reconstruction Using the Deep Inferior Epigastric Artery Perforator Flap: A Proof-of-Concept Study.

Authors:  Hidehiko Yoshimatsu; Ryo Karakawa; Yuma Fuse; Tomoyuki Yano
Journal:  J Clin Med       Date:  2022-01-21       Impact factor: 4.241

6.  Primary Prevention of Cancer-Related Lymphedema Using Preventive Lymphatic Surgery: Systematic Review and Meta-analysis.

Authors:  Pedro Ciudad; Joseph M Escandón; Valeria P Bustos; Oscar J Manrique; Juste Kaciulyte
Journal:  Indian J Plast Surg       Date:  2022-02-25

7.  Five-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1-4N1-3M0 Breast Cancer.

Authors:  Kelly M Herremans; Morgan P Cribbin; Andrea N Riner; Dan W Neal; Tracy L Hollen; Pamela Clevenger; Derly Munoz; Shannon Blewett; Fantine Giap; Paul G Okunieff; Nancy P Mendenhall; Julie A Bradley; William M Mendenhall; Raymond B Mailhot-Vega; Eric Brooks; Karen C Daily; Coy D Heldermon; Julia K Marshall; Mariam W Hanna; Mark M Leyngold; Sarah S Virk; Christiana M Shaw; Lisa R Spiguel
Journal:  Ann Surg Oncol       Date:  2021-08-07       Impact factor: 5.344

8.  Real-Time Visualization of the Mascagni-Sappey Pathway Utilizing ICG Lymphography.

Authors:  Anna Rose Johnson; Melisa D Granoff; Hiroo Suami; Bernard T Lee; Dhruv Singhal
Journal:  Cancers (Basel)       Date:  2020-05-08       Impact factor: 6.639

9.  Improving the quality of life of patients with breast cancer-related lymphoedema by lymphaticovenous anastomosis (LVA): study protocol of a multicentre randomised controlled trial.

Authors:  Joost Wolfs; Jop Beugels; Merel Kimman; Andrzej A Piatkowski de Grzymala; Esther Heuts; Xavier Keuter; Hanneke Tielemans; Dietmar Ulrich; R van der Hulst; Shan Shan Qiu
Journal:  BMJ Open       Date:  2020-01-15       Impact factor: 2.692

10.  Correlation between patency and clinical improvement after lymphaticovenous anastomosis (LVA) in breast cancer-related lymphedema: 12-month follow-up.

Authors:  Joost A G N Wolfs; Luuke G E H de Joode; René R W J van der Hulst; Shan S Qiu
Journal:  Breast Cancer Res Treat       Date:  2019-09-21       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.